Literature DB >> 8613381

Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.

G H Lowell1, R W Kaminski, S Grate, R E Hunt, C Charney, S Zimmer, C Colleton.   

Abstract

Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphylococcal enterotoxin B (SEB) toxoid in saline elicited higher anti-SEB serum immunoglobulin G (IgG) titers when the toxoid was formulated with proteosomes. In addition, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-SEB IgA in lung and intestinal secretions, whereas the toxoid without proteosomes did not. Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine serum responses than alum-adjuvanted toxoid without proteosomes. Furthermore, proteosome-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant protection against lethal SEB challenge in two D-galactosamine-sensitized murine models of SEB intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge model of mucosal SEB exposure. Efficacy correlated with the induction of high serum levels of anti-SEB IgG. In contrast, intranasal or i.m. immunization with toxoid in saline without proteosomes was not significantly protective in either challenge model. Proteosome-toxoid plus alum given i.m. also elicited more significant protection against respiratory challenge than the alum-adjuvanted toxoid alone. The capacity of proteosomes to enhance both i.m. and intranasal immunogenicity and efficacy of SEB toxoid indicates that testing such proteosome-SEB toxoid vaccines in the nonhuman primate aerosol challenge model of SEB intoxication prior to immunogenicity trials in humans is warranted. These data expand the applicability of the proteosome mucosal vaccine delivery system to protein toxoids and suggest that respiratory delivery of proteosome vaccines may be practical for enhancement of both mucosal and systemic immunity against toxic or infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613381      PMCID: PMC173982          DOI: 10.1128/iai.64.5.1706-1713.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Effect of X irradiation on survival of rabbits with staphylococcal B enterotoxemia.

Authors:  C T Liu; D E Hilmas
Journal:  Radiat Res       Date:  1978-11       Impact factor: 2.841

2.  Biodegradable microspheres: vaccine delivery system for oral immunization.

Authors:  J H Eldridge; R M Gilley; J K Staas; Z Moldoveanu; J A Meulbroek; T R Tice
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

3.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

4.  Gangliosides and membrane receptors for cholera toxin.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

5.  Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits.

Authors:  G Hajishengallis; S K Hollingshead; T Koga; M W Russell
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

6.  Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide).

Authors:  R Edelman; R G Russell; G Losonsky; B D Tall; C O Tacket; M M Levine; D H Lewis
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

7.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

8.  Selective expansion of T cells expressing V beta 2 in toxic shock syndrome.

Authors:  Y Choi; J A Lafferty; J R Clements; J K Todd; E W Gelfand; J Kappler; P Marrack; B L Kotzin
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

9.  Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants.

Authors:  G H Lowell; L F Smith; R C Seid; W D Zollinger
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.

Authors:  T Miethke; C Wahl; K Heeg; B Echtenacher; P H Krammer; H Wagner
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  22 in total

1.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.

Authors:  Dong-Liang Hu; Jing-Chun Cui; Katsuhiko Omoe; Hiroshi Sashinami; Yuichi Yokomizo; Kunihiro Shinagawa; Akio Nakane
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

6.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Authors:  G H Lowell; C Colleton; D Frost; R W Kaminski; M Hughes; J Hatch; C Hooper; J Estep; L Pitt; M Topper; R E Hunt; W Baker; W B Baze
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 7.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 8.  Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor.

Authors:  Gang Chen; Hatice Karauzum; Hua Long; Danielle Carranza; Frederick W Holtsberg; Katie A Howell; Laura Abaandou; Bojie Zhang; Nick Jarvik; Wei Ye; Grant C Liao; Michael L Gross; Daisy W Leung; Gaya K Amarasinghe; M Javad Aman; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2019-03-27       Impact factor: 5.469

9.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

10.  Detection of Protein Toxin Simulants from Contaminated Surfaces by Paper Spray Mass Spectrometry.

Authors:  William R A Wichert; Elizabeth S Dhummakupt; Chengsen Zhang; Phillip M Mach; Robert C Bernhards; Trevor Glaros; Nicholas E Manicke
Journal:  J Am Soc Mass Spectrom       Date:  2019-03-11       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.